Cizzle Biotechnology Holdings PLC Companion Diagnostic Supply Agreement with SGSC (8733P)
22 Octubre 2021 - 1:00AM
UK Regulatory
TIDMCIZ
RNS Number : 8733P
Cizzle Biotechnology Holdings PLC
22 October 2021
22 October 2021
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Companion Diagnostic Supply Agreement with St George Street
Capital
Research and Development agreement worth up to GBP1 million
signed for potential autoimmune disease testing and possible
additional companion diagnostics
Cizzle Biotechnology, the UK based diagnostics developer, is
pleased to announce it has executed a research and development
agreement to develop a companion diagnostic test for autoimmune
disease with St George Street Capital ("SGSC"), the UK-based
biomedical charity. The new diagnostic platform will be used to
develop tests that will operate alongside SGSC's programme for the
development of therapeutic assets licensed to SGSC from one of the
world's largest pharmaceutical companies, Astra Zeneca. This seeks
to address unmet clinical needs in a wide variety of autoimmune
diseases which will significantly broaden the Company's product
pipeline and for which SGSC will pay Cizzle Biotechnology up to
GBP1 million in development fees.
As announced on 20 September 2021, Cizzle Biotechnology signed
an agreement with SGSC to grant Cizzle Biotechnology potential
future royalty payments from the commercialisation of St George
Street's therapeutic asset AZD1656 of up to GBP5 million. This
followed SGSC's announcement on 9 September 2021 of encouraging
clinical trial results arising from their existing collaboration
with AstraZeneca and funded by international investment through
Excalibur Medicines Ltd and an HM Government grant through the
UKRI/Innovate UK programme.
This new commercial contract with SGSC will seek to provide
valuable diagnostic information on patients based on the proposed
mechanism of action of AZD1656 which may be linked to the
regulation of inflammation through activating migration of T
regulatory cells to sites of damaging inflammation. Migration of T
regulatory cells amplify the body's own mechanism of damping down
an inappropriate inflammatory overreaction and hence may have
important clinical benefits in managing autoimmune disease.
Under the commercial contract entered into, the parties will
collaborate closely in the design and development of the test and
in consideration SGSC will pay Cizzle Biotechnology GBP200,000
upfront on commencement of the project and then further milestone
payments totalling up to GBP1 million. A further announcement will
be made when the project commences.
Commenting, Allan Syms, Executive Chairman of Cizzle
Biotechnology, said: "We announced on 20 September following SGSC's
successful ARCADIA clinical trial, a royalty agreement related to
AZD1656. We are now also delighted to sign a new R&D agreement
with SGSC to develop a companion diagnostic which has fees payable
to Cizzle Biotechnology of up to GBP1 million. This will strengthen
the two parties' close relationship through the development of a
companion diagnostic test for the use of their therapeutic asset
that is aimed at addressing unmet needs in the area of autoimmune
disease. A potential pipeline of new diagnostic tests for SGSC will
significantly broaden Cizzle Biotechnology's product portfolio as
we continue to develop our simple blood test for the early
detection of lung cancer based on the C1Z1B biomarker."
Commenting, Professor John Martin of UCL, Chairman of SGSC,
said: "We announced last month the encouraging clinical trial
results of our new treatment for COVID-19 and completed our formal
royalty sharing agreement with Cizzle Biotechnology. Today we are
pleased to extend that relationship through the signing of a new
agreement to collaborate in the development of a companion
diagnostic for use with our therapeutic asset AZD 1656 for
autoimmune disease. We continue to be impressed with the progress
of this long-term relationship with Cizzle Biotechnology, which
combines unique skills, experience and capabilities from each party
to build complimentary diagnostic and therapeutic products of
important clinical utility."
This announcement contains inside information for the purposes
of article 7 of EU Regulation 596/2014 which forms part of domestic
UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK
MAR") . Upon the publication of this announcement this inside
information is now considered to be within the public domain.
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 3328 5656
John Depasquale
Alex Brearley
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of a majority of the different forms of lung cancer.
Cizzle Biotechnology is a spin- out from the University of York,
founded in 2006 around the work of Professor Coverley and
colleagues. Its proof-of-concept prototype test is based on the
ability to detect a stable plasma biomarker, a variant of CIZ1
known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein
involved in the cell growth and division cycle, and the targeted
CIZ1B variant is highly correlated with early stage lung
cancer.
For more information please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
About St George Street Capital
St George Street Capital is a biomedical research charity on a
mission to fast-track clinical trials so we can get new treatments
as quickly as possible to the people who need them. We apply bold
new thinking to unlock the therapeutic potential of therapies and
science currently sitting on the shelf in pharma. We are a new type
of charity, sourcing investment to accelerate clinical trials,
where new science shows great potential and where patients and
clinicians are calling out for treatments. St George Street Capital
was established in 2017 and brings together a powerful mix of
expertise, from investors and business managers to academics and
clinicians.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRMZMZGVMRGMZM
(END) Dow Jones Newswires
October 22, 2021 02:00 ET (06:00 GMT)
Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024